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Abstract: Overexpression and secretion of the enzymes cathepsin D (CathD) and cathepsin L (CathL)
is associated with metastasis in several human cancers. As a superfamily, extracellularly, these
proteins may act within the tumor microenvironment to drive cancer progression, proliferation,
invasion and metastasis. Therefore, it is important to discover novel therapeutic treatment strategies
to target CathD and CathL and potentially impede metastasis. Graphene oxide (GO) could form
the basis of such a strategy by acting as an adsorbent for pro-metastatic enzymes. Here, we have
conducted research into the potential of targeted anti-metastatic therapy using GO to adsorb these
pro-tumorigenic enzymes. Binding of CathD/L to GO revealed that CathD/L were adsorbed onto
the surface of GO through its cationic and hydrophilic residues. This work could provide a roadmap
for the rational integration of CathD/L-targeting agents into clinical settings.
Keywords: graphene oxide; adsorption; cathepsin D; cathepsin L; anti-metastatic enzyme cancer
therapy
1. Introduction
Every year more than 2.28 million new cases of breast and ovarian cancers are diagnosed
worldwide, principally in developed countries and 807,440 women die of them [1–3], with these
cancers representing the first and fifth most common cause of female malignancies, respectively [4,5].
Although these diseases have different pathologies they share a common set of molecular mechanisms
such as the misfolding/aggregation, overexpression and hypersecretion of specific proteins typically
involved in degrading cross-linked, abnormal, short-lived self- and foreign- proteins in lysosomes and
phagocytosis. The intracellular and extracellular responses of the tumor microenvironment tend to
be more prominent in response to conditions such as acidic pH [6], the enhanced permeability and
retention effect [7], the enzyme abundance in the tumor extracellular matrix, [8] and overexpression of
particular cell membrane receptors [9]. Typically, this emanates from the misfolding of proteins which
potentially tend to form pathogenic aggregates, including harmful oligomeric and/or cytotoxic factors
involved in the molecular etiology of these diseases and other pathologies (which are linked with
the ability of the proteins to fully execute their physiological functions provided by certain regions
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of their protein sequence) [10]. When the intracellular protein degradation within the cells’ acidic
endosomal/lysosome compartments increases, the proteolytic activity becomes particularly high in
lysosomal proteases such as cathepsin D (CathD) and cathepsin L (CathL). However, in tumor invasion
and development, these enzymes play a significant role by extracellularly influencing cell proliferation,
differentiation, cell migration, programmed cell death, angiogenesis, immune defence, inflammation
and extracellular tissue remodelling [11,12].
Higher CathL and CathD concentrations are closely related to an increased risk of metastasis [13].
For example, CathL is considered to be associated with tumor invasion and metastasis, by degrading
subunits of extracellular matrix including proteoglycans, elastin, entactin (nidogen), laminin,
fibronectin, perlecan and interstitial and basement-membrane collagens. Recently, we showed a
significantly higher expression of CathL in the omentum hosting metastatic ovarian serous carcinoma
compared with omentum from normal and benign controls with ovarian cystadenoma. We found that
exogenous CathL induced pro-angiogenic effects on omental microvascular endothelial cells which
may aid metastasis [14]. Recent studies have investigated the enhanced immunohistochemical CathD
expression as an indicator of potential malignancy in serous ovarian cancer [13]. For example Losch et
al. [15] demonstrated that CathD was detected in more than 70% of invasive ovarian cancers. Secreted
CathD from breast cancer cells and its proteolytic role in degrading ECM proteins and subsequently
releasing growth factors such as bFGF, have also been reported, which provide an ability for cancer
cells to invade nearby tissue [16,17]. Misfolding, overexpression and hypersecretion of CathD and
CathL have now been demonstrated in numerous cancer types such as ovarian, breast, lung and
prostate, endometrial, as well as malignant glioma and melanoma and are recognized as critical
players in cancer biology by regulating diverse proteolytic functions in triggering the breakdown of
the tumor basement membrane and fueling tumor invasion [18–21]. Adsorption of these enzymes to
two-dimensional materials opens a window of opportunity to develop a wide range of new approaches
in the prevention of cancer.
Nanotechnology and its underpinning sciences have significantly contributed to the improvement
of nanodrug bioavailability and therapeutic index in cancer therapy [22]. Recently, graphene oxide
(GO) formulations have been developed into adaptable nanoscale platforms for medical interventions
as one of the most sophisticated and minimally toxic tools [23] that permit direct contact with,
and manipulation of, the intracellular environment. Graphene is a two-dimensional sheet composed
of a single layer of sp2-hybridized carbon atoms arranged in a honeycomb lattice [24]. Graphene and
its analogues have attracted tremendous interest over the last decade for use in biomedicine owing to
their unique physicochemical and mechanical properties, interesting optical and electronic properties,
large surface area and good biofunctionality [25]. GO has many advantages over conventional
nanosheets and other derivatives of graphene, such as a small size, chemical inertness, high specific
surface area, photo-stability, good water solubility, high drug loading capacity, high purity, good
fluorescence capability and biocompatibility. These properties make GO a promising candidate in
novel delivery systems for target-specific therapeutic drugs and for the diagnosis of different medical
conditions as well as for wound healing [26,27]. Furthermore, GO could offer a potential therapeutic
tool by adsorbing the pro-metastatic enzymes, which are cancer-associated factors. GO has a large
interfacial area and spatial constraints for biological interaction, ideally suited to constructing a
robust and cost-effective extracellular tumor-specific enzyme binding method [28]. This capability
of GO to bind and track an active enzyme could open the door to new clinical algorithms based on
‘enzyme-targeted therapy’. GO nanoformulations which take up these enzymes could be key enablers
of novel anti-metastatic enzyme therapy by breaking down the functional and structural integrity of
extracellular enzymes. These GO nanoplatfoms offer a simple, safe and robust strategy in boosting the
concept of ‘anti-metastatic enzyme-targeted therapy’, a neologism coined to indicate an innovative
and revolutionary approach useful to adsorb and treat ‘pro-tumorigenic’ enzymes with a number of
outcomes: notably the clearance of these enzymes, their structural breakdown, their digestion to active
site-directed specific adsorbents and the deregulation of pro-tumorigenic enzymes. It is generally
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understood that the biocompatibility of graphene-based materials is limited by their sharp edges
and two-dimensional monolayered structures, which is evident from concentration-dependent toxic
effects in numerous cell lines. Targeting and therapeutic adsorption of CathD and CathL in cancer
treatment are currently unknown and undefined. The process of enzyme adsorption, and its therapeutic
efficacy are affected by several factors such as: the properties of proteins and their concentrations
in solution; pH and ionic strength; the temperature of the medium; pH-dependent adsorption
performance; the structural stability of proteins; the selection and nature of adsorbent, porous
sites/vacancies in adsorbents to take up the proteins; and strength/stability of adsorbate-adsorbent
interface. The mechanistic aspects of protein adsorption and/or protein corona formation as a result of
the interaction of proteins with graphene may involve electrostatic and hydrophobic interactions [29].
The intrinsic stability of the adsorbent matrix structure, which can be revealed by undergoing structural
rearrangements, and conformational alterations, resulting in protein denaturation and/or loss of
functional activities and a change in surface energy, allows a wide range of chemical changes in
functional groups and wettabilities. The established method of fluorescence quenching and absorbance,
together with vibrational spectrometry, wetting transparency, adsorption kinetics, and regression
analysis can be used to reveal the fundamental aspects of the enzyme-graphene interaction and to
address a variety of pre-clinical unknowns in the same theranostic session.
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Figure 1. Proposed mechanism of cathepsin function in cancer metastasis and use of graphene oxide 
(GO) as an adsorbent to remove cathepsin from a living system. There are three panels in this diagram: 
(1) role of cathepsins in cancer progression: (2) structure of GO and its parameters relevant to the 
adsorption of cathepsins: and (3) the mechanism of adsorption. The left panel (1) illustrates possible 
tumorigenic and proangiogenic roles of cathepsin D (CathD) and cathepsin L (CathL) within the 
cancerous stroma or extracellular matrix (ECM) on endothelial cells (EC) acting via an unknown 
receptor(s) (RCP). The bottom panel (2) shows the structure of GO. This is prepared from graphite 
using the modified Hummer’s method [26–28]. GO has suitable properties for the efficient adsorption 
of these enzymes such as surface charge, surface area, functional groups, electronic and chemical 
properties. The right panel (3) shows the potential mechanism involved in enzyme internalization, 
the interaction of GO with CathD/CathL and the further breakdown of cathepsins which may lead to 
cathepsin removal. Electrostatic and van der Waals forces, osmotic depletion and solvophobicity play 
a pivotal role in adsorption of such enzymes. 
Figure 1. Proposed mechanism of cathepsin fu cti in cancer metastasis and use of graphene oxide
(GO) as an adsorbent to remove cathepsin from a living system. There are three panels in this diagram:
(1) role of cathepsins in cancer progression: (2) structure of GO and its parameters relevant to the
adsorption of cathepsins: and (3) the mechanism of adsorption. The left panel (1) illustrates possible
tumorigenic and proangiogenic roles of cathepsin D (CathD) and cathepsin L (CathL) within the
cancerous stroma or extracellular matrix (ECM) on endothelial cells (EC) acting via an unknown
receptor(s) (RCP). The bottom panel (2) shows the structure of GO. This is prepared fr m graphite
using the modified Hummer’s method [26–28]. GO has suitable properties for the efficient adsorption
of these enzymes such as surface charge, surface area, functional groups, electronic and chemical
properties. The right panel (3) shows the potential mechanism involved in enzyme internalization,
the interaction of GO with CathD/CathL and the further breakdown of cathepsins which may lead to
cathepsin removal. Electrostatic and van der Waals forces, osmotic depletion and solvophobicity play a
pivotal role in adsorption of such enzymes.
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Secretion of CathD and CathL poses a unique therapeutic challenge in breast and ovarian cancers.
Therefore, a fuller clearance of these proteins before their involvement in secondary tumour progression
may help advancement of treatment modalities. We have previously reported on the expression and
secretion of CathL and CathD in the omentum and ascites of ovarian malignant patients, as well as in
the tumor-based conditioned media ovarian cancer cell lines [14]. In the present paper, we report the
use of GO to investigate whether CathD and CathL might be cleared out through an adsorption process.
To help visualize the role that GO plays, we used a cost-effective and scalable batch adsorption approach,
where complementary information is channeled via multimodal kinetic and regression models as an
analogy of a multiplexed toxicity-dependent clearance of pro-metastasis enzymes. Our study reveals
that inhibition of CathD and CathL could indeed help overcome the therapeutic challenges faced in
breast and ovarian cancers. The idea of enzyme-targeting therapy is explained in Figure 1.
2. Results
2.1. Synthesis and In Vitro Toxic Effects of GO on Lung Cancer Cells
Similar to our previously reported work, exfoliated GO was synthesized following the modified
Hummer’s method [30–32]. The basic characterization is given in Supplementary Note 1 and Figures
S1–S9. TEM imaging showed the flake-like shapes of GO (Figure S1). We first characterized GO,
referred to as GO sheets, indicating atomic compositions of C (1s) and O(1s) as 91%, and 9%
(Figure S2A), respectively. The binding energy of 285.0 eV was related to the C−C, C=C, and C−H
bonds (Figure S2B). The other C1s peaks of GO contained three main components belonging to
C−O (hydroxyl and epoxy, 286.7 eV), C=C/C−C (284.7 eV) and O=C−O (carboxyl, 288.8 eV) and a
minor component of the C=O (carbonyl, 287.4 eV) and O=C−OH (289.1 eV) functional groups [33].
The Raman spectrum of GO (Figure S3) exhibited a D band at 1358 cm−1 (the presence of defects) and
a G band at 1595 cm−1 (the in-plane stretching motion of pairs of sp2 atoms) [34]. The surface area of
the GO was measured by the N2 absorption Brunauer−Emmett−Teller (BET) method and found to
be 25 m2/g with a pore volume of 0.07 cm3/g (Figure S4). The surface charge of the GO sheets was
determined by the zeta potential measurements (Figure S5). The GO sheets were highly negatively
charged (−63.54 mV) due to the presence in their molecular structure of the carboxyl group in the
free state. Furthermore, the FTIR spectrum of GO (Figure S6) showed the specific functional groups
of C−O−C (~1000 cm−1), C−O (1230 cm−1), C=C (~1620 cm−1) and C=O (1740–1720 cm−1) bonds.
The band in the region of 3600–3300 cm−1 corresponds to O−H stretching vibrations of hydroxyl and
carboxyl groups of GO [35]. The Lambert–Beer law, which describes the linear relationship between
the absorbance and the concentration of the compound in a given solution was used to examine the
dispersibility of GO. A calibration curve was constructed by measuring the absorbance at 232 nm of
nine different concentrations (0.039–10 mg/mL) of the GO solution, in which there was good water
dispersibility of GO (Figure S7) [36]. The XRD pattern of GO, as prepared in the present study, gave a
(001) reflection peak at 2θ = 13.7◦ (Figure S8), which corresponds to a d-spacing of 0.75 nm, and exhibits
an increased interlayer distance compared to that (3.34 Å) (2 theta 1/4 26.7◦) in the typical graphite
oxide structure (sp2 hybridization) [37]. This suggested the complete disintegration of the graphite
structure to form GO under ultra-sonic vibration. Initially, GO exhibited weight loss of 8.7 wt% at
temperature below 150 ◦C as a result of the loss of absorbed water, while in second stage GO lost
more weight (23.6 wt%) in the temperature range of 180–250 ◦C due to thermal decomposition of
oxygen-containing functional groups including hydroxyl and epoxy (Figure S9).
The in vitro toxic effects of GO were determined by measuring cell viability, early and late
apoptosis, and necrosis in two well-characterized lung cancer cell lines at different concentrations of
GO (5–500 µg/mL). We measured both early and late apoptosis, where the latter can be distinguished
from the former by the presence of a disintegrated cell membrane (detected by PI internalization).
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by flow cytometry and analysed using Guava 3.1.1 software. Percentage cell counts are shown for (A) living cells, (B) early apoptosis, (C) late apoptosis and (D) 
necrosis at increasing concentrations of GO. Data from three independent experiments are presented as mean ± SD. Groups are indicated as n.s and * p < 0.05, 
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Figure 2A demonstrates a slight but significant (p < 0.05) reduction in cell viability of both A549
and SKMES-1 cells after 24 h GO exposure statistically at concentrations of 250 and 500 µg/mL,
compared to the control group (0 µg/mL). Significant early apoptosis was also detected (Figure 2B),
in A549 cells at 500 µg/mL of GO (p < 0.05) compared to controls (0 µg/mL), and in SKMES-1
cells at 50 and 250 µg/mL of GO (p < 0.05) compared to controls. Late apoptosis (Figure 2C) and
necrosis (Figure 2D) measurements were also carried out for A549 cells. Interestingly, in SKMES-1 cells,
250 and 500 µg/mL of GO significantly induced late apoptosis while necrotic cells were detected at GO
concentrations of 50–500 µg/mL. Figure 2E illustrates the representative analysis of one flow cytometry
experiment in SKMES-1 and A549. GO induced apoptosis and necrosis at concentrations higher than
50 µg/mL in both cell lines. However, the percentage count of apoptotic cells remained higher
compared to necrosis, suggesting that GO may not cause significant damage to the cell membrane,
allowing only the binding of annexin V to PS on the cell surface membrane. This indicates that the cell
death observed at higher concentrations of GO is probably due to apoptosis rather than necrosis.
For the toxicity exposures undertaken, GO has been shown to be less toxic than other forms of
graphene such as reduced GO, which we recently reported for similar cell lines [38]. However, GO
has proven to be more toxic than graphene quantum dots as reported by Zhu et al. [39] where it was
demonstrated that quantum dots have little toxicity to MG63 (80–90% of cell viability at low dose).
This may be because dots are smaller than GO, and hence cause less damage to the cell membrane. GO
has been proven to be less cytotoxic, with a reduced free radical production, and cell death compared
to reduced GO because of the two-dimensional nature of thin sheets, functional groups and surface
charges of GO that allows its efficient cellular uptake [40]. Oxidative stress is thought to be a key factor
resulting in graphene toxicity, reducing the number of viable cells and hindering uptake of essential
proteins and nutrients [41]. Furthermore, GO may induce various levels of toxicity in in vitro and
in vivo models as a result of concentration and dosage patterns, administration routes, entry paths
and accumulation of GO via barriers, distribution among different organs, cellular uptake, localisation
and clearance [42]. These biological mechanisms depend on physio-chemical properties, sheet size,
shape, lateral dimension, functional groups, surface charge and hydrodynamic diameter of the GO. It is
evident that a sheet size of GO below 40 nm does not cause off-target toxicity [43–45]. We have explored
the in vitro toxicity of GO in cancer cells at various concentrations, giving insights into the safe and
biocompatible doses of GO to be used for the adsorption and clearance of enzymes. Our results
demonstrate that GO at low concentrations did not exhibit obvious toxicity and did not interrupt the
course of cell metabolism, gene transcription or cell death. Owing to the flake-like shape of the GO
sheet, a readily available surface area is provided to adsorb enzymes while remaining non-toxic to
healthy surrounding tissues. However, the neurotoxicity and neuroprotection of GO towards brain
cells remain largely unknown and still need further research to explore the possible mechanism of
interaction between GO and brain cells, and the capacity of GO not to cross the blood-brain barrier,
in improving therapeutic responses to GO.
2.2. Basic Characterization of Enzymes
The proteolytic activity of CathD was investigated using a specific fluorogenic substrate at the
two pHs, 3.6 and 7, while the proteolytic activity of CathL was investigated using the CathL-specific
fluorogenic substrate ZVA (5 nM) at the two pHs 5 and 7. CathD was more active at pH (3.6). When the
pH was increased to 7, the fluorescence signals were observed to be reduced (Figure 3A). The result
suggests that CathD is not proteolytically active at neutral pHs. On the other hand, CathL was more
active at pH 5.5 (Figure 3B). Fluorescence signals remained almost two times higher than the control at
pH 7 (pH of the cell culture medium). The data suggested that CathL is proteolytically active at pH 7.
The representative FTIR spectra of CathD and CathL are given in Figure 3C for the spectral
range (3200–500 cm−1). In the case of CathD, most of the observed bands appearing at 1100, 1243,
1280, 1413, 1713, and 2050–2150 cm−1 are C−O stretch, CH wagging, C−O stretch, carboxylate ion
(COO−) symmetry, C=O stretch carboxylic acid and C−H alkyl stretch respectively [46,47]. The most
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prominent band assignments of CathL at 1100, 1243, 1280, 1413, 1713, and 2050–2150 cm−1 are C−O
stretch, CH wagging, C−O stretch, carboxylate ion (COO−) symmetry, C=O stretch carboxylic acid
and C−H alkyl stretch respectively [46–48]. These bands were not observed in control experiments
without CathD/CathL and substrate agents (data not shown). The regions with the widest ranges
and their corresponding spectral signatures have been given in Table S1. The representative Raman
spectra of CathD and CathL are given in Figure 3D for the spectral range (500–2500 cm−1). The most
prominent band set of the CathD are 2243, 2024 and 1603 cm−1 while assignments of CathL are 2024
and 1603 cm−1. The prominent peak at 1608 cm−1 relates to the known bands for the Fmoc group as
reported earlier [49]. The Raman bands at 2024 and 2243 cm−1 could be assigned to the C≡C stretching
vibration, which was present in the propargyl group [49]. The surface free energy and its polar and
dispersive parts were calculated to investigate the binding capacity and weight of electrostatic and/or
van der Waals interactions between GO and the enzymes. The binding capacity of GO, CathD and
CathL were calculated using the contact angle method and their respective contact angles have been
shown in Figure 3E. The surface free energies, polar and dispersive parts of GO, CathD and CathL are
shown in Figure 3F. CathD has the highest total surface energy of 77.4 mN/m, although GO, CathD
and CathL have similar trends of surface energies of total and their respective parts because of the
similar amount and weight of functional groups. As a result, the use of GO as an adsorbent could allow
enzymes to be adsorbed and substituted to improve the binding of CathD/CathL with GO. Therefore,
it appeared that amino-acid replacement at the basal planes of GO can lead to protein-ligand binding.
(See set of “snapshots” in Figure 3G).
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2.3. Enzyme Interaction with GO
Batch adsorption studies were performed to measure the effect of pH on the adsorption process
of CathD and CathL using GO as an adsorbent. Figure 4 shows absorbance variations at different
concentrations of GO (0, 50, 500 and 1000 µg/mL) mixed with CathD and CathL at different time
points (0–20 min). The decrease in absorbance signals of CathD and CathL at pH’s of 3.6 and
5, respectively revealed the amount of CathD and CathL adsorbed to GO. At optimal incubation
times and concentrations of GO, CathD and CathL were almost fully adsorbed onto the GO surface.
The CathD and CathL adsorption process was found to be pH-dependent and concentration-dependent,
demonstrating that the highest adsorbed amounts were at more acidic pHs (3.6 and 5). For pH 3.6,
the amount of CathD adsorbed increased from 50 to 1000 µg/mL over a time scale of 0 to 20 min.
The adsorption capacity of GO (1000 µg/mL) was above 90% after 20 min. CathL adsorption onto the
GO surface followed a similar pattern at pH 5 and at 1000 µg/mL GO the highest value of efficiency
was attained after 20 min. Figure 5 shows that an increase in adsorption capacity occurred for both
enzymes over a 20 min time period, reaching a maximum capacity of above 90%. The capacity was
found to be slightly greater for higher concentrations of GO. The results are in good agreement with
experimental data (Figure 6A,B).
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Adsorption kinetics are useful to evaluate the adsorption process and adsorption rate. In this
study, we have used an intraparticle diffusion model. This multi-linearity graph plot of intraparticle
diffusion shows three segments: the first portion is the instantaneous adsorption segment which shows
the adsorption of external surface of GO; the second step is the gradual adsorption stage assigned to
intraparticle diffusion; and the third straight portion depicts the final equilibrium stage due to the
low adsorbate concentration left in the solution. Figure 6A,B show that the intraparticle diffusion
plot at each concentration did not pass through the origin, indicating that the intraparticle diffusion
was not the only rate-controlling process. This is indicative of an additional role of boundary layer
diffusion control. The intraparticle diffusion constant values are shown in Table S2. Gaussian process
regression models for CathD and CathL relating independent variables (time and concentrations) to
the dependent variable of adsorption are shown in Figure 5C–F. In Figure 5C,E, the mean predictions
for CathD and CathL are depicted respectively, and the uncertainty in these predictions has been
shown in Figure 5D,F. The mean predictions for CathD indicate that promising (lower) absorption
can be achieved with a concentration of around 100 µg/mL when CathD is incubated with GO for
15 to 20 min. The models also revealed that concentrations of CathD greater than 900 µg/mL which
are incubated for about 18 min could also be promising. Figure 5E,F show similar trends for CathL.
The fluorescence of GO only has been shown in Figure S10. Figure S11 illustrates the measurement
of normalised fluorescence intensities of various concentrations of GO (0, 50, 500 and 1000 µg/mL)
exposed to CathD and CathL at different time points (0–20 min). CathD and CathL were enzymatically
cleaving a GO substrate which gave rise to a fluorescent product, at increasing concentrations of
GO (0, 50, 500 and 1000 µg/mL). GO was able to concentration-dependently increase the catalytic
activity of CathD and CathL at all pHs tested. A slight difference in emission spectra also occurs,
suggesting that lower pH values represent an improved exposure of non-polar sites of adsorbate in
the enzymes. Fluorescence loss was observed in the case of CathL at pH 7, due to the reversible nature
of CathL inhibition. The lack of any significant difference in fluorescence signals might be because
of the adsorption of enzymes induced by GO. This uptake allows localization of internalized GO
under different pH conditions [50,51]. This uptake could be attributable to the large size of GO which
blocks fluorescence signals. The binding of CathD and CathL to GO shows that both the enzymes
and GO sheets form a new tertiary structure. These tertiary structures may contribute significantly
to the self-fluorescence characteristics of GO. Understanding the pre-clinical and clinical effects of
such factors to allow the development and adsorption of pro-tumorigenic and pro-metastatic enzymes,
released into the extracellular matrix from malignant tumors, will be the focus of further studies.
FTIR and Raman spectroscopic findings can be used to monitor the macromolecular movements
and vibrational/rotational states of specific chemical groupings which bind target biomolecules with
high specificity during the formation of the nano-bio-interface of CathD- and CathL-GO. Figure 6A,B
illustrates FTIR spectra of GO-CathD/CathL at the concentrations of 50, 500 and 1000 µg/mL of GO
after 20 min. The FTIR spectrum of CathD-linked GO revealed a range of CathD and CathL absorption
bands including C=O (υC=O at 1714 cm−1), and the peak of the C−N stretch mode (υC=O at 1100 cm−1)
at all the concentrations represents the CH stretching and NH bending. The specific band of GO-CathD
(at two concentrations of 500 and 1000 µg/mL GO) (Figure 6A) showed the characteristic peak of
an alkoxy group at 980 cm−1 which is associated with the C=O functional groups of GO and CathD.
The peaks at 1413 cm−1, ascribed to NH bending and CN stretching, also confirmed the presence of
CathD and CathL. Figure 6C,D show Raman spectra of GO-CathD/CathL. The amide-1 vibration at
1590 cm−1 arose from the typical υC=O stretching vibration. The band in the range of 2020–2250 cm−1
was assigned to the specific C−H3 and C−H2 deformation vibrations which mainly arose from the
side chains of different amino acids. The band in the range of 1200–1340 cm−1 was assigned to
the amide-III vibration which typically arose from the combination of the N-H bending and C−C
stretching vibration [52,53]. In the Raman spectra of GO and GO-CathD/CathL, the slight shifting
of peaks towards lower wavenumber can be observed. GO has two typical peaks at ca. 1355 cm−1
and 1580 cm−1. The spectra at 1600–1620 cm−1 can be assigned to the C=O stretching of carboxylate
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and C−H2 deformation vibrations. Based on these bands, it is concluded that the CathD and CathL
interacted with GO through its amide groups. Both cathepsins have a deep bonding pocket with the
binding groups identified by FTIR, which are held together with GO by electrostatic attractions.
The functional groups present at the outermost surface of GO readily facilitate its coverage
with inert molecules, which increases surface hydrophilicity and subsequently enhances the bonding
strength of these nanostructures [54]. Several site-specific variants of GO have been employed in
attempts to alter the surface-inactivation of ‘wild-type’ enzymes. The extent of enzyme absorption
(and the mechanistic insight this provides in relation to the proteins’ interactions with surfaces)
have been probed by water contact angle (WCA) measurements and surface energy determinations
(Figure 6E,F). The CathD and CathL displayed higher binding activity towards GO, as demonstrated
by the WCA values. Upon CathD and CathL interactions, the WCA profiles of GO shifted to higher
values, suggesting that a good level of surface hydrophilicity was achieved (Figure 6F). The effect
was more pronounced for the higher concentrations, whose average WCA value increased by 8.5
and 15.0 degrees for CathD and CathL, respectively. The changes in diiodomethane contact angle
(Figure 6F) showed the surface energy profile (Figure 6G,H). The binding free energies of GO to
CathD and CathL are shown in Figure 6G,H. The intermolecular vdW and electrostatic interactions
are believed to improve the desolvation process because of the substitution of one oxygen-containing
functional group with an amino group, which in turn increases the total free energy of the compound.
However, the polar penalties upon binding of these two proteins to GO were decreased.
These findings have provided significant information about the surface interactions of GO sheets
with CathD and CathL: (i) the number and amount of the functional groups and their reactivity;
(ii) the critical role of surface hydrophobicity in the adsorption process. The WCA of CathD and CathL
is shown in Figure 3. Moreover, the key differences in the amount and number of functional groups
and bonding affinities are responsible for the rise in total and dispersive surface energy. The low
polar and high dispersion parts (Figure 6G,H) of the surface energy profiles revealed that the polar
and nonpolar side-chains of CathD/CathL facilitate conformational alterations in the CathD/CathL
structure, which in turn lead to a high adsorption capacity of GO for CathD/CathL.
3. Discussion
Potential cancer therapies include the development of innovative treatment modalities that
are capable of clearing the pro-tumorigenic enzyme by developing a novel platform based on
biocompatible adsorbents. The currently available mainstream treatment options have resulted in
improved survival and quality of life, although ovarian and breast cancers remain progressive diseases.
Thus, there is an ever-growing need for the development of alternative approaches. Conventional
biological drug therapies have limitations due to unwanted side effects on normal tissues/cells that
adversely affect the efficacy and safety of the treatment. The emerging paradigm of personalised
and precision medicine provokes the concept that adsorption of these enzymes in the local tumor
environment could be achieved by using porous adsorbents. Enzyme-targeted therapy provides a
great opportunity for this by addressing the mechanisms of pro-tumorigenic enzyme clearance and
therapeutic action. In this study, we developed a GO that breaks down and takes up enzymes which
promote increased invasiveness and metastasis. The surface charge, surface area, chemical reactivity
and electronic characteristics of GO were used to target these enzymes with sustained release of
functional groups, free radical and porous sites for entrapment of CathD and CathL. The inhibition
of CathD and CathL was observed at specific pH values which support metastasis. Inhibition of
CathD and CathL was verified by enzyme activity using specific substrates. The analysis of the
released CathD and CathL libraries was carried out using a wide variety of analytical tools such as
FTIR, Raman, WCA and surface energy profiles (see Figure 2; Figure 6), thus posing a significantly
fast-tracked identification procedure and considerable output compared with conventional tools to
analyse nanoparticle interactions with proteins. In this manner, the characterization of the studied
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enzymes for their binding and bioactivity is carried out to better understand their structural and
functional behaviours.
The current approach of enzyme targeting offers a number of important advantages over
conventional approaches. First, it permits the simplistic tagging of cathepsins with very high
transformation/removal efficiencies using GO, which considerably increases the likelihood of
recognising biomolecular fractions. Secondly, the clinical relevance and biosafety of this modality
would further benefit from utilising a GO system that is already used in clinical trials to introduce
drug/gene carrier vehicles. Finally, the approach presented here is greatly adaptable and can be used
largely for the innovation of theranostic saviours of disease-associated enzymes. The present work was
mainly applied to targeting two ovarian and breast cancer-associated enzymes. The two-dimensional
and adsorbing nature of GO could reduce the likelihood of abundance of these enzymes to induce
tumor cell invasion and metastasis, and thereby maximize the broad applicability of GO. Furthermore,
the GO not only allows for robust interactions with enzymes but also enables the compact packaging of
the GO within dissolvable capsules, facilitating non-invasive oral administration to track these proteins,
which could be used as a diagnostic tool. Given the clear benefits achievable by using enzyme-targeted
therapy (compared with the currently available modalities such as chemotherapy, radiation therapy
etc.), the cost-effectiveness involved in producing GO is another advantage for implementing this
material as a standard-of-care in the treatment of cancer. Currently, clinical-scale manufacturing of GO
entails a range of protocols to fabricate, modify, functionalise, deliver and selectively accumulate and
administrate into the living systems. Future work will address cell-based and pre-clinical metastatic
disease models and will possibly include further developments to integrate targeted and safe delivery
of GO to the tumor sites with sufficient selectivity to facilitate the removal of disseminated enzymes.
4. Experimental Section
4.1. Synthesis and Characterization
Exfoliated graphene oxide (GO) flakes were synthesized from exfoliated graphite using the
modified Hummer’s method as previously reported by us [27,28,38]. NaNO3 (1.5 g) and H2SO4
(150 mL, 98%) were added to a 800 mL round-bottom flask with graphite flakes (2 g). The reaction
mixture was mixed under magnetic stirring following by the immersion of the flask in an oil bath.
The mixture was then heated at the temperature of 35 ◦C, before adding KMnO4 (9 g) into the flask.
The mixture was subjected to constant continuous stirring for 24 h, followed by addition of more
H2SO4 (280 mL, 5%) and the temperature was increased to 85–95 ◦C. The mixture was stirred for
another 2 h before removing the bath. The flask was allowed to cool down to 60 ◦C. Finally, H2O2
(15 mL, 30 wt%) was added and the mixture was stirred for another 2 h. The resultant product was
washed 7–8 times with HCl (3 wt%) and then washed 4–5 times with distilled water to eliminate any
contaminants. As obtained GO was dispersed in water under stirring. As prepared GO was then used
for further characterization. Transmission electron microscopy (TEM) (JEOL-2100 TEM, JEOL, Madrid,
Spain), at an accelerating voltage of 200 kV) was used to obtain high resolution microstructural images.
A drop of the as prepared GO was deposited on a holey carbon Cu grid to prepare the TEM samples.
X-ray diffraction (XRD) analysis was conducted using Cu Kα radiation. X-ray measurements were
performed at a voltage of 40 kV and a current of 40 mA and spectrum was collected a step size of 0.02◦
(2θ) and a step time of 1 s. Fourier-transform infrared (FTIR) spectroscopy was conducted by means of
a Tensor-27 FTIR spectrometer (Bruker Optics, Champs-sur-Marne, France) in the wavenumber range
of 4000–500 cm−1. FTIR samples were prepared by mixing the sample with KBr. Raman spectroscopy
was carried out with laser excitation at 532 nm (Renishaw, Stroud, UK). To calculate the surface charge
of GO, zeta potential measurements were performed using a colloidal dynamics zeta probe. UV/Vis
spectrophotometry was performed using a 6715 UV–Vis instrument (Jenway, Staffordshire, UK).
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4.2. Cell Viability
Cell viability experiments using flow cytometry has been described elsewhere [34]. Briefly,
cells were treated with or without 5, 50, 250, 500 and 1000 µg/mL of GO for 24 h. After trypsinisation,
cells were stained with annexin V (BioLegend, London, UK) and propidium iodide (PI, Sigma-Aldrich,
Gillingham, Dorset, UK)) and subjected to flow analysis using a Guava flow cytometer (Millipore UK
Limited, Hertfordshire, UK). The data were analysed using the Guava 3.1.1 software. The experiment
was carried out at least three times and the data obtained were analysed using GraphPad Prism 5.04
(GraphPad Software, San Diego, CA, USA), and expressed as % cell count ± SD, Mann Whitney.
4.3. Regression Model
We were particularly interested in determining a good estimate of the most effective level of
concentration of CathD and CathL and the experiment time required for biological applications.
As such we built a model that may indicate which pair of concentrations and times are promising
and subsequently help in our decision making. However, we had limited data (due to the expense of
conducting many experiments) and repeated measurements are always noisy (in that we obtained a
slightly different measurement for the same concentration and time). Therefore, it is of paramount
importance to consider these uncertainties in modelling the performance of these enzymes. Standard
non-linear regression models usually predict the general trend without capturing such uncertainties.
As an alternative, we used Gaussian processes (GPs) to model absorption (dependent variable) with
respect to time and concentration (independent variables) for both CathD and CathL. A GP model
allowed us to inspect the expected performance and the predictive uncertainty for the enzymes.
Thus we were able to strike a balance between predicted performance and uncertainty to make an
informed decision.
Formally, a GP may be considered as a collection of random variables, which is jointly Guassian
distributed [38,52]. This essentially allows us to encapsulate the intuition that for a small change in
concentration and time there should be a small change in performance. Let D = {xi, yi} be a data set
consisting of n data points, where the i-th vector xi consists of a time and a concentration (independent
variables), and yi is the associated absorption (dependent variable). A trained GP model then produces
the following posterior predictive Gaussian distribution: P(yn+1|xn+1, D, θ) ~ N(µ(xn+1), σ(xn+1)),
where θ is a set of hyperparameters that are optimised using collected data D, µ(xn+1) is the expected
performance for xn+1, and σ(xn+1) is the predictive uncertainty. The details of training a GP model can
be found in [52].
4.4. Water Contact Angle Measurements and Surface Energy Calculations
A contact angle goniometer was used to calculate the wettability of GO, CathD and CathL.
A digital camera was used to capture the images and the contact angle was measured using the ImageJ
processing program. The contact angle surfaces were developed by dropping a 10 µL drop onto a glass
slide. The surface free energies were estimated by quantifying the contact angle of diiodomethane
(DIIO) on the surface of the sample. 10 µl drop of DIIO was used in each measurement. The surface
free energy of a solid sample is expressed by Young’s equation, where S is solid and L is liquid:
σS = σSL + σL × cosθ (1)
where σL, and σSL represent the surface tension of the liquid and the interfacial tension between the
liquid and the solid, respectively and θ is the contact angle shaped by the liquid on the surface of the
sample respectively. Here, we are measuring σS with the help of known value of σL and unknown
value of σSL. According to the Fowkes method [53], the surface tension is given by:
σSL = σL + σS - 2((σLD × σSD)1/2 + (σLP × σSP)1/2) (2)
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where the surface free energies are mixture of dispersive (D) and polar (P) parts together. This would
be used to exclude the unknown value in Equation (1).
The polar part of liquid is zero for DIIO, so:
σS
D = σL × (cosθ + 1)2/4 (3)
where σL = σLD = 50.8 mN/m. The dispersive part of the surface free energy of the sample can directly
be found from the contact angle.
The polar and dispersive parts of water are: σLD = 26.4 mN/m and σLP = 46.4 mN/m. Equations
(1) and (2) can be reorganised to calculate the polar part of the surface energy of the sample:
σS
P = (σL × (cosθ + 1)/2 - (σLD × σSD)1/2)2/σLP (4)
If the values of the dispersive and polar parts are known, the total surface energy of the sample
will be:
σS = σSD + σSP (5)
Contact angles of water and DIIO on surface of GO are 33.4◦ and 20◦ respectively. The dispersive
component, polar component and total surface energies of GO are 42.8, 29.6 and 72.4 mN/m
respectively [53]. The other surface energies were calculated in the same manner.
4.5. Proteolytic Activities
Citrate and phosphate buffer solutions were prepared at pHs 3.6, 5.0 and 7.0. Their composition
is given in Supplementary notes 2 and 3. The measurement of proteolytic activities has been described
elsewhere [18,20]. A brief description of each enzyme activity is presented below:
4.6. CathD Experiment
The buffers required to test CathD-proteolytic activities contained 0.005% of Tween20
(Sigma-Aldrich) and the pHs were adjusted to 3.6 and 7. CathD-fluorogenic substrate (100 nM;
Enzo Life Sciences, Exeter, UK) was incubated ± CathD (50 ng/mL; recombinant from human liver,
Sigma-Aldrich) and plates were read after 60 s of shaking at Ex/Em: 320/393 nm.
4.7. CathL Experiment
The buffers contained 1 mM DTT to disrupt the disulfide bonds, resulting in an active enzyme.
CathL fluorogenic substrate Z-Val-Val-Arg-AMC (ZVA; 5 nM) was incubated ± CathL (50 ng/mL;
recombinant from human liver, Sigma-Aldrich) at pHs 5 and 7. The plate was shaken for 60 s in a
plate-reader prior to fluorescence reading at Ex/Em: 365/440 nm.
Both enzyme activities were measured using a SpectraMax plate reader (Molecular Devices UK
Limited, Berkshire, UK). The data was normalised to control and represented as a percentage of
the control.
4.8. Enzyme Interaction with GO
An interaction between CathD or CathL (50 ng/mL) and GO (50, 500 and 1000 µg/mL) was
tested in pH buffers (pHs 3.6 and 7 for CathD, and pHs 5.5 and 7 for CathL). pH values of 3.6 and
5.5 are optimum for CathD and CathL activity, respectively. CathD and/or CathL was incubated
with GO at different concentrations for 2, 5, 10, 15 and 20 min. The experiment was performed in
×4 96 well black opaque plates (Greiner Bio-One Ltd., Gloucestershire, UK). Plates were read at the
same time scale as previously mentioned, of incubation at room temperature to measure absorbance at
280 nm for CathD and CathL using a SpectraMAX plate reader. The data normalised to the control
and represented as a percentage of this control. The fluorescence intensity of the GO hydrolysis was
identified kinetically using a SpectraMax plate reader. This was repeated (n = 4) with CathL at different
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concentrations of GO (50, 500 and 1000 µg/mL). The control wells contained GO only. FTIR, Raman
spectroscopy, wettabilities and surface energies were carried out in the same manner as explained in
the previous section.
To verify the adsorption of CathD and CathL, an intra-particle diffusion model was used. Fick’s
second law was used to find out the intraparticle diffusion model as a rate-determining step during the
adsorption experiment. It was carried out to verify whether it may control the kinetics of adsorption
process [54,55]:
qt = kid
√
t+ I (6)
where I represents the boundary layer effect (a large value corresponds to a larger boundary layer
thickness and kid is the intraparticle rate constant and kint (g/mg min1/2) and C represent the adsorption
constant and the intercept, respectively [56,57]. The intercept is measured from the plot of qt versus t1/2.
4.9. Statistical Analysis
Statistical analysis was carried out between two groups by the Mann-Whitney test, and between
multiple groups were compared by one-way analysis of variance (ANOVA) with Tukey post-hoc testing
or two-way ANOVA with a Bonferroni post-hoc test, using GraphPad Prism 5 software. The results
are shown as mean ± s.d, (standard deviation) unless otherwise indicated. The value of p < 0.05 was
considered statistically significant.
5. Conclusions
In summary, our findings represent a straightforward and highly reliable approach for the rapid
and facile removal of pro-metastasis enzymes. GO with its variable zeta potential, variety of functional
groups and very large (and in principle fully accessible) surface area, is an extremely promising
candidate for the adsorption of such enzymes. Our results show that this material is compatible
with cells. In addition, the adsorbent preparation is based on abundantly available and cost-effective
graphite as the main precursor. Graphene oxide nanostructures are straightforward to prepare and are
highly stable, which streamlines long-term storage at room temperature and correspondingly eases the
manufacturing cost. Therefore, if employed in clinical settings as an innovative platform, this highly
adaptable strategy could provide a real-world, cost-effective and broadly relevant procedure to treat
chronic and complex diseases.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/3/319/s1,
Figure S1: Transmission electron microscopy image of graphene oxide, Figure S2: Basic characterization of
exfoliated graphene oxide (GO). (A) XPS survey. (B) The C1s spectrum of the GO shows three main components
arising from C−O (hydroxyl and epoxy, 286.7 eV), C=C/C−C (284.7 eV) and O=C−O (carboxyl, 288.8 eV) and a
minor component of the C=O (carbonyl, 287.4 eV) and O=C−OH (289.1 eV) species, Figure S3: Raman spectrum
of the graphene oxide sample shows intense D (1358 cm−1) and G peaks (1595 cm−1) of defects and the in-plane
stretching motion of pairs of sp2 atoms, respectively, Figure S4: BET surface area of graphene oxide measured by
nitrogen sorption isotherms measured at –196 ◦C. The BET surface area value obtained for this sample using the
BET method was 25 m2/g, Figure S5: Representative zeta potential of graphene oxide over a range of different
pH values, Figure S6: The Fourier transformed infrared (FTIR) spectrum of graphene oxide shows vibrations of
functional groups of C−O−C (~1000 cm−1), C−O (1230 cm−1), C=C (~1620 cm−1), C=O (1740–1720 cm−1) bonds
and O−H (3600–3300 cm−1), Figure S7: (A) UV/Vis absorption spectra of graphene oxide solutions with different
concentrations (from 0.039–10 mg/mL) show the main peak around 232 nm. (B) The plot of the absorbance
(λ = 232 nm) divided by the cell length, versus the concentration. The Lambert–Beer law (A = α × C × l), allowed
the determination of the absorption coefficient (α). This linear relationship fits well with the Lambert-Beer Law,
indicating the good water solubility of the GO product, Figure S8: The XRD pattern recorded from graphene
oxide shows a (001) peak at 2θ of 13.7◦, Figure S9: TGA of exfoliated graphene oxide. TGA was performed in the
nitrogen atmosphere, Figure S10: Photoluminescence emission spectrum of graphene oxide, Figure S11: Effect of
different concentrations of GO on CathD and CathL fluorescence activities. GO at different concentrations (50, 500,
and 1000 µg/mL) were incubated with CathD (A, B) and CathL (C, D) in 96 well plates at different time-points
(2, 5, 10, 15, and 20 min) as shown where RFU is relative fluorescence units. Fluorescence signals were determined
using a plate reader at Ex/Em: 355/450 nm. Each data point represents the mean of n = 4 experiments. Bars show
SDs, Table S1: Characteristic IR bands of the protein linkages, Table S2: Kinetic parameters obtained for CathD
and CathL for GO using an intraparticle diffusion model.
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